Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RB-ADSC-03
- Development stage
- Unknown
- Lead developer
- Regeneration Biomedical
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intrathecal
01
Overview
RB-ADSC-03 (CEREWiNT®) is an autologous adipose-derived stem cell (ADSC) therapy developed by Regeneration Biomedical for the treatment of neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis. The therapy involves isolating stem cells from the patient's own adipose tissue, which are then expanded, enriched, and engineered to express Wnt signaling pathway components and neuronal lineage markers. These modified cells are delivered directly into the brain's ventricular system via a surgically installed reservoir (e.g., Ommaya reservoir). The mechanism of action aims to promote neuronal repair, neuroprotection, and regeneration by leveraging the regenerative potential of stem cells and the neurotrophic effects of Wnt signaling activation, which is critical for neurogenesis and synaptic plasticity.
- Brand names
- CEREWiNT
- Other names
- autologous adipose-derived stem cell therapy
Beyond the preview
Go deeper on RB-ADSC-03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RB-ADSC-03.